End-of-day quote
Shenzhen S.E.
03:30:00 07/06/2024 am IST
|
5-day change
|
1st Jan Change
|
36.63
CNY
|
-0.38%
|
|
-6.51%
|
-37.85%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16,890
|
8,215
|
7,071
|
4,386
|
-
|
-
|
Enterprise Value (EV)
1 |
16,890
|
8,215
|
7,071
|
4,386
|
4,386
|
4,386
|
P/E ratio
|
76.8
x
|
60.5
x
|
46
x
|
23.3
x
|
17.3
x
|
16.7
x
|
Yield
|
0.71%
|
1.46%
|
1.53%
|
1.94%
|
2.45%
|
2.29%
|
Capitalization / Revenue
|
43.9
x
|
17.3
x
|
13
x
|
6.83
x
|
5.4
x
|
4.7
x
|
EV / Revenue
|
43.9
x
|
17.3
x
|
13
x
|
6.83
x
|
5.4
x
|
4.7
x
|
EV / EBITDA
|
81.1
x
|
34
x
|
35.3
x
|
22.8
x
|
15.8
x
|
16.1
x
|
EV / FCF
|
-
|
-
|
-404
x
|
37.8
x
|
26.3
x
|
20.3
x
|
FCF Yield
|
-
|
-
|
-0.25%
|
2.65%
|
3.81%
|
4.93%
|
Price to Book
|
6.85
x
|
3.21
x
|
2.73
x
|
1.63
x
|
1.5
x
|
1.46
x
|
Nbr of stocks (in thousands)
|
1,20,000
|
1,20,000
|
1,19,970
|
1,19,726
|
-
|
-
|
Reference price
2 |
140.8
|
68.46
|
58.94
|
36.63
|
36.63
|
36.63
|
Announcement Date
|
14/04/22
|
25/04/23
|
23/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
385
|
474.4
|
543.7
|
642.6
|
812.4
|
932.2
|
EBITDA
1 |
-
|
208.2
|
241.7
|
200.1
|
192.4
|
277
|
271.8
|
EBIT
1 |
-
|
195.6
|
216.5
|
161.1
|
187.9
|
255
|
281.2
|
Operating Margin
|
-
|
50.82%
|
45.62%
|
29.63%
|
29.24%
|
31.39%
|
30.17%
|
Earnings before Tax (EBT)
1 |
-
|
195.4
|
215
|
160.7
|
187.3
|
254.5
|
280.6
|
Net income
1 |
115.9
|
174.2
|
203.7
|
153.6
|
188.3
|
254.5
|
264
|
Net margin
|
-
|
45.25%
|
42.94%
|
28.25%
|
29.3%
|
31.33%
|
28.31%
|
EPS
2 |
1.287
|
1.834
|
1.132
|
1.280
|
1.569
|
2.120
|
2.200
|
Free Cash Flow
1 |
-
|
-
|
-
|
-17.49
|
116
|
167
|
216
|
FCF margin
|
-
|
-
|
-
|
-3.22%
|
18.05%
|
20.56%
|
23.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
60.31%
|
60.3%
|
79.47%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
61.62%
|
65.62%
|
81.83%
|
Dividend per Share
2 |
-
|
1.000
|
1.000
|
0.9000
|
0.7100
|
0.8967
|
0.8400
|
Announcement Date
|
08/04/21
|
14/04/22
|
25/04/23
|
23/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
---|
Net sales
1 |
146
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
30.67
|
Net margin
|
21.01%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
23/04/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-17.5
|
116
|
167
|
216
|
ROE (net income / shareholders' equity)
|
-
|
27.4%
|
8.13%
|
5.98%
|
7.19%
|
8.53%
|
8.72%
|
ROA (Net income/ Total Assets)
|
-
|
6.85%
|
7.72%
|
-
|
5.97%
|
6.97%
|
7.8%
|
Assets
1 |
-
|
2,545
|
2,640
|
-
|
3,155
|
3,653
|
3,384
|
Book Value Per Share
2 |
-
|
20.60
|
21.40
|
21.60
|
22.50
|
24.40
|
25.10
|
Cash Flow per Share
2 |
-
|
1.150
|
1.680
|
0.9300
|
1.370
|
1.620
|
2.170
|
Capex
1 |
-
|
61.7
|
284
|
129
|
82
|
60.4
|
74.1
|
Capex / Sales
|
-
|
16.01%
|
59.85%
|
23.67%
|
12.77%
|
7.44%
|
7.95%
|
Announcement Date
|
08/04/21
|
14/04/22
|
25/04/23
|
23/04/24
|
-
|
-
|
-
|
Last Close Price
36.63
CNY Average target price
56.78
CNY Spread / Average Target +55.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.85% | 61Cr | | +45.82% | 77TCr | | +40.95% | 63TCr | | -6.16% | 35TCr | | +19.86% | 33TCr | | +9.32% | 30TCr | | +18.45% | 25TCr | | +11.88% | 22TCr | | -0.78% | 22TCr | | +5.90% | 16TCr |
Other Pharmaceuticals
|